SENORES Senores Pharmaceuticals Q3 FY26 results (Oct–Dec 2025) and concall
Senores Pharmaceuticals delivered a strong Q3 FY26, with consolidated revenue growing 64% YoY to INR175 crores and PAT increasing 85% to INR32 crores. The company completed the acquisition of 75% stake in Apnar Pharma, which is expected to significantly boost regulated market revenue and capacity. Growth was broad-based across regulated markets, emerging markets, and India branded generics, supported by a robust product pipeline and strategic capital allocation.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 66.0%, net profit up 112.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 101 | 103 | 114 | 138 | 162 +60% | 171 +66% |
| EBITDA | 23 | 26 | 19 | 34 | 50 +117% | 50 +92% |
| Net profit | 13 | 16 | 18 | 21 | 30 +131% | 34 +113% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
